ArticleFrontiers in pharmacology2024
Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07234916 (The Impact of Multivitamin Supplementation on Micronutrient Levels in GLP-1 Users), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Multivitamin Supplementation on Micronutrient Levels in GLP-1 Users: A Randomized, Double-Blind, Placebo-Controlled Trial
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists.Vision (Basel, Switzerland) · 2026Review
- Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017-2024.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2026Article
- GLP-1 guidelines amid an obesity epidemic: a poor fit for the Global South.Archives of public health = Archives belges de sante publique · 2026Article
- Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity.Nutrients · 2026Review
- Analysis and mining of adverse events associated with vorapaxar: A FAERS database-based study.PloS one · 2026Article
- Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.Drug, healthcare and patient safety · 2026Article
- The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials.Diabetology & metabolic syndrome · 2025Article
- Neurological complications associated with rapid weight loss and nutritional deficiencies following GLP-1 agonist use: a case report.BMC neurology · 2025Article
- Bridging pharmacovigilance and genetic insight: investigating drugs and indications for breast cancer risk in women with autoimmune diseases.Journal of translational medicine · 2025Article
- GLP-1 Receptor Agonists - Good for Body Weight, Bad for Micronutrient Status?Current developments in nutrition · 2025Article
- Exploring Dietary Intake in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists: A Cross-Sectional Analysis.Nutrients · 2025Article
- The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes.Current atherosclerosis reports · 2025Review
- Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment.Nutrients · 2025Review
- Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes.Nutrients · 2025Review
- Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes.medRxiv : the preprint server for health sciences · 2025Article
- Decoding the impact of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist on cardiometabolic health: inflammatory mediators at the focus.Diabetology & metabolic syndrome · 2025Article
- A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.Drug design, development and therapy · 2025Review
- Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.